

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA LONGEVITY GROUP COMPANY LIMITED**

### **中國龍天集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1863)**

### **UPDATE ON SUSPENSION OF TRADING**

This announcement is made by China Longevity Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.24A of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 13 June 2014, 18 September 2017, 1 August 2018, 26 October 2018, 9 November 2018, 11 December 2018, 11 February 2019, 30 April 2019, 18 June 2019, 2 August 2019, 4 November 2019, 3 February 2020, 31 July 2020, 3 November 2020, 29 January 2021, 11 May 2021, 28 July 2021, 29 October 2021, 27 January 2022, 29 April 2022 and 29 July 2022 (the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements.

### **BUSINESS UPDATE**

The Board would like to provide an update to the shareholders of the Company that the Company’s production, operation, and finance remain healthy, and it will continue to focus on the research and development of new materials and products.

### **SUSPENSION OF TRADING**

The shares of the Company have been suspended from trading on the Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) since 14 February 2013.

As previously provided in the Company’s Announcement on 18 June 2019, the Stock Exchange had confirmed that it would, until further notice, withhold exercising its right to delist the Company under Rule 6.01A(2)(b)(ii) should the trading in the Company’s securities remain suspended on 31 July 2019.

As of the date of this announcement, the Company has not received any notice from the Stock Exchange stating that it is proceeding to delist the Company.

## **THE REGULATORY CONCERNS OF THE SFC**

On 23 December 2019, the Company, upon the suggestion of the Securities and Futures Commission (“**the Commission**”), submitted a written representation to the Board of the Commission (“**the Board**”) pursuant to Section 9 of the Securities and Futures (Stock Market Listing) Rules (“**SMLR**”) to address the concerns raised by the Commission in its “Show Cause Letter” dated 24 November 2014 (“**the Resumption Application**”).

According to a letter from the Commission Secretary to the Enforcement Division of the Commission (“**ENF**”) dated 8 May 2020, the Board had considered the Resumption Application at its meeting on 7 May 2020. The said meeting was adjourned for the Board to seek clarifications from ENF on several questions.

According to a letter from the Commission Secretary to the ENF and the Company dated 5 March 2021, the Board had considered the Resumption Application at its adjourned meeting on 22 February 2021. The said meeting was again adjourned pending further information from the Company.

The Company understands that up to the date hereof the Board has not made a decision on the Resumption Application and may seek further information from the Company.

The Company will make further announcement(s) to keep the Shareholders informed of the latest development as and when appropriate.

**Trading of shares of the Company has been suspended since 14 February 2013 and will remain suspended until further notice.**

By order of the Board  
**China Longevity Group Company Limited**  
**Lin Shengxiong**  
*Executive Director*

Hong Kong, 28 October 2022

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Lin Shengxiong, Mr. Huang Wanneng, Mr. Jiang Shisheng and Mr. Liu Jun, and three independent non-executive Directors are Mr. Lau Chun Pong, Mr. Lu Jiayu and Ms. Jiang Ping.*